Amgen, MD Anderson partner to develop T cell immunotherapies

Amgen Inc. (NASDAQ:AMGN) and the University of Texas MD Anderson Cancer Center partnered to develop Amgen's early stage immunotherapies including CAR T therapies and bispecific T cell engager antibody constructs through two multiyear collaborations.

The first five-year collaboration will begin with Phase I studies of BiTE antibody constructs and CAR T therapies for multiple myeloma and small cell lung cancer. The second, four-year collaboration will include preclinical and clinical studies of BiTE, CAR T and small molecule therapies to treat leukemia and myelodysplastic syndromes, and will look for new biomarkers for the diseases. Both will focus on Amgen's therapies nearing clinical development or in initial clinical testing...